Credit Suisse lowered its price target on Coherus Biosciences (NASDAQ: CHRS) to $24.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change FDA

Coherus Biosciences (CHRS) PT Lowered to $33 at CitiJune 13, 2017 6:27 AM Coherus Biosciences (CHRS) Neulasta Biosimilar Delay 'Appears Resolvable' - CowenJune 12, 2017 12:29 PM Coherus Biosciences (CHRS) PT Lowered to $43 at BMO Capital; 'CHS-1701 CRL Disappointing but Issues Addressable - Buy on Weakness' June 12, 2017 12:03 PM Coherus Biosciences (CHRS) PT Lowered to $37 at Baird Following FDA Letter June 12, 2017 11:33 AM Pre-Open Movers 06/12: (TROV) (GTXI) (GE) Higher; (CHRS) (AMD) (AAPL) Lower (more...)June 12, 2017 9:31 AM Wall St. falls as Apple drags tech shares lowerJune 12, 2017 7:40 AM Coherus BioSciences (CHRS) Receives CRL from FDA for CHS-1701 BLAJune 12, 2017 6:38 AM